Stephan's Thursday Picks

• McCormick posts lower profits on higher sales (WSJ)
• A French recipe for shock au vin (Globe and Mail)
• The Canadian scientist behind Ozempic on why he never, ever gave up (Be Giant)
• P&G's chief on whether brand loyalty is enough when prices keep climbing (NYT)
• America's restaurants face a dilemma: How to sell food in the GLP-1 era (NYT)

 Stephan's Wednesday Picks

• Lindt to cut prices on as chocolate demand wanes in key markets (Bloomberg)
• How three young restaurateurs revived London's oldest chophouse (FT)
• Potato by air (The Verge)
• Lab-grown meat: Moral mission meets market realities (FT)
• The next frontier for obesity drugs isn't how much weight you lose, but what kind (WSJ)

 Stephan's Wednesday Picks

• New weight-loss pills curb snacking less than GLP-1 shots (Bloomberg)
• US in talks to buy potash from Belarus at lower cost than what Canada charges, Trump says (Globe and Mail)
• New Zealand opposition vows to boost grocery sector competition (Bloomberg)
• Amazon drones overwhelm a Texas suburb (NYT)
• Amazon, Swiggy among firms facing India food regulator's action (Bloomberg)

 Stephan's Monday Picks

• Mark Carney has become the heir to CD Howe (Globe and Mail)
• The highest returning stock in the last 45 years is Home Depot (WSJ)
• Hating on polyester is back in fashion (Bloomberg)
• Russia seizes control over Nestle and Auchan operations (FT)
• For food companies, shifts from GLP-1s are hard to digest (NYT)

 Stephan's Friday Picks

• This is your home on GLP-1s (Architectural Digest)
• Coca-Cola reached for nostalgia. Did it get Marlboro instead (NYT)
• Apotex emerges as only manufacturer of generic Ozempic for now (Globe and Mail)
• The unsexy habit that turned a college dropout into a $300 million founder (Forbes)
• From the archives (2018): The other side of Barry Sherman (Maclean's)

 Stephan's Thursday Picks

• More Americans than ever are taking weight-loss drugs (NYT)
• Food and beverages have gone bananas (NYT)
• Wild coffee swings usher in new era of market volatility (Bloomberg)
• Walmart announced price cuts. Trump tried to take credit (NYT)
• White House pressures top US grocers on beef prices (WSJ)

 Stephan's Tuesday Picks

• GLP-1 users are taking a bite out of restaurants (WSJ)
• Why are life is now on subscriptions (NYT)
• The shoppers redefining how to save money on groceries (NPR)
• The world is awash in bourbon. That's a problem for big booze (WSJ)
• Do you have a mango dealer (FT)

 Stephan's Monday Picks

• The State of Grocery Retail Europe 2025 (McKinsey)
• Ottawa announces $6 billion to boost skilled trades, smaller deficit projection of $66.9 billion (Globe and Mail)
• Health Canada approves generic Ozempic from Apotex as patients and insurers seek savings (Globe and Mail)
• The day the food noise died (NYT)
• New weight loss drugs like Ozempic can also erase people's love of food (Globe and Mail)

 Stephan's Tuesday Picks

• Roger Martin: Fixing strategy (Medium)
• Lululemon blames customers again after see-through leggings fiasco (Bloomberg)
• America's convenience store conundrum (The Atlantic)
• With generic Ozempic coming to Canada, the race is on (Globe and Mail)
• Nestle's chief is in turnaround mode. He drinks eight cups of coffee a day (NYT)

 Stephan's Wednesday Picks

• Gourmet Magazine is back It's not exactly sanctioned (NYT)
• Former Neiman Marcus chief is picked to lead Saks through bankruptcy (WSJ)
• Shopify embraces agentic AI with Google, Microsoft partnerships (Globe and Mail)
• Daily Bread to cut off Scarborough food bank after reporting financial concerns to police (CBC)
• Ozempic users actually spend more dining out. Smart restaurants are adapting (Bloomberg)

 Stephan's Friday Picks

• EQ Bank to buy PC Financial from Loblaw for $800 million (Globe and Mail)
• Thomson, Weston families win bid for Hudson's Bay charter (Globe and Mail)
• You're on Ozempic? How quaint (The Atlantic)
• Ozempic is changing the way we spend money on time, and the way we eat (Washington Post)
• From the archives (2002): Thomson legacy likely to endure (Globe and Mail)

 Stephan's Wednesday Picks

• Ozempic killed diet and exercise (The Atlantic)
• How an app selling second-hand clothes went from near collapse to worth $5 billion (WSJ)
• The state of grocery retail in Latin America (McKinsey)
• Kroger-Albertsons merger blocked by the courts (WSJ)
• Trump won't be able to save the struggling US beef industry (Bloomberg)

 Stephan's Thursday Picks

• Metro plans to open more discount stores next as inflation-hit shoppers hunt for value (Globe and Mail)
• Target's stock plunges 21% on weak sales ahead of holiday season (NYT)
• Alleged potato cartel accused of conspiring to raise prices of frozen fries, tater tots across U.S. (CBC)
• Ozempic could crush the junk food industry. But it is fighting back (NYT)
• Canada's largest bottled water producer to pull out of Ontario (Globe and Mail)

 Stephan's Friday Picks

• Ozempic is changing the way people eat. Snack companies are paying close attention (CBC)
• Windsor has a problem: Not enough tech workers to work on their farms (Globe and Mail)
• Your old clothes are worth billions (WSJ)
• Want an iced coffee. Brands want you to make your own (WSJ)
• From the archives (2022): What we write about when we write about food (NYT)

 Stephan's Tuesday Picks

• Roger Martin: How to be a good board member (Medium)
• Will Americans ever get sick of cheap junk (The Atlantic)
• Rising food prices send more shoppers to Aldi (WSJ)
• How supplement stores are trying to tap into the Ozempic boom (NYT)
• Billionaire Geiger nears $7 billion L'Occitane buyout sources say (Bloomberg)

 Stephan's Monday Picks

• California's fast-food chains are now serving sticker shock (WSJ)
• It introduced Ozempic to the world. Now it must remake itself (NYT)
• The era of one-stop grocery shopping is over (WSJ)
• Founder of Freshii suing company that bought his restaurant chain (Globe and Mail)
• You know LVMH for its bags. It's also a titan of real estate (WSJ)

 Stephan's Monday Picks

• Brands are concerned about how they're perceived by ChatGPT (Fast Company)
• Daniel Kahneman: The unlikely economist (Morningstar)
• Here's who should pay for everyone's Ozempic (Slate)
• People are fed up with Loblaw's store prices. Would a boycott accomplish anything (CBC)
• Canada's unemployment rate jumps to 6.1% as job creation stalls (Globe and Mail)

 Stephan's Friday Picks

• $7 million for 30 seconds? To advertisers, the Super Bowl is worth it (NYT)
• 'Scared' food CEOs are calling Ozempic maker for advice (Bloomberg)
• Who created butter chicken? India's great curry clash (NYT)
• Sainsbury's to cut costs by £1 billion and launch share buyback (FT) 
  
• From the archives (2020): Want to be more productive? Try doing less (HBR)

 Stephan's Wednesday Picks

• AI fuels a new era of product placement (NYT)
• Should Amazon be responsible for everything it sells and ships (WSJ)
• What if Ozempic is just a good thing (New York Magazine)
• HMV makes comeback through Toys 'R' Us locations (Financial Post)
• Manulife backtracks plan to give Loblaws exclusive right to fill prescriptions for some drug plan members (Globe and Mail)

 Stephan's Friday Picks

• Where is the brand growth potential? An examination of buyer groups (Byron Sharp)
• 10 things I know about food - that people don't want to believe (Washington Post)
• The 'Ozempic effect' on Wall Street has gone overboard (WSJ)
• Years into a climate disaster, these people are eating the unthinkable (Washington Post)
• From the archives (2010): How Sobeys is taking on Loblaw (Globe and Mail)